Skip to main content

Year: 2025

Generac Reports Third Quarter 2025 Results

Growing data center market opportunities provide counterweight to below average power outage environment WAUKESHA, Wisc., Oct. 29, 2025 (GLOBE NEWSWIRE) — Generac Holdings Inc. (NYSE: GNRC) (“Generac” or the “Company”), a leading global designer and manufacturer of energy technology solutions and other power products, today reported financial results for its third quarter ended September 30, 2025 and provided an update on its outlook for the full-year 2025. Third Quarter 2025 HighlightsNet sales decreased 5% to $1.11 billion during the third quarter of 2025 as compared to $1.17 billion in the prior-year third quarter. Core sales, which excludes both the impact of acquisitions and foreign currency, decreased approximately 6%.Residential product sales decreased approximately 13% to $627 million as compared to $723 million last...

Continue reading

Constellium Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Guidance

PARIS, Oct. 29, 2025 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) (“Constellium”, the “Company” or the “Group”) today reported results for the third quarter and the nine months ended September 30, 2025. Third quarter 2025 highlights:Shipments of 373 thousand metric tons, up 6% compared to Q3 2024 Revenue of $2.2 billion, up 20% compared to Q3 2024 Net income of $88 million compared to net income of $8 million in Q3 2024 Adjusted EBITDA of $235 million      > Includes positive non-cash metal price lag impact of $39 million Segment Adjusted EBITDA of $90 million at A&T, $82 million at P&ARP, $33 million at AS&I, and $(9) million at H&C Cash from Operations of $99 million and Free Cash Flow of $30 million Repurchased 1.7 million shares of the Company stock for $25 millionNine months...

Continue reading

Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management

SHANGHAI, Oct. 29, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) today announced the signing of a strategic collaboration agreement in Shanghai, ahead of World Psoriasis Day. Fangzhou’s Founder, Chairman and CEO Dr. Xie Fangmin and Li Mei, Co-CEO of Fosun Pharma’s Domestic Marketing Platform, attended the signing ceremony on behalf of the companies. Fangzhou and Fosun Pharma plan to build an extensive partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune conditions. The companies will jointly pursue flagship digital health initiatives that integrate AI-assisted patient education, academic research...

Continue reading

Form 8.3 – Inspecs Group Plc

Downing LLPLEI: 213800G3X76VBG9SB50429 October 2025Form 8.3 re. Inspecs Group Plc PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Downing LLP(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):Client funds managed by Downing LLP(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:Inspecs Group Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: n/a(e)   Date position held/dealing undertaken:28 October 2025(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect...

Continue reading

Notice of regulatory approval of the sale of Northern Horizon Capital AS shares

Northern Horizon Capital AS, the management company of Baltic Horizon Fund, hereby notifies that on 27 October 2025, the Estonian Financial Supervision and Resolution Authority approved the sale of all 12,500 shares in Northern Horizon Capital AS from the current sole shareholder Northern Horizon A/S (registered in Denmark under register number 27599397) to Antanas Anskaitis, Antanas Danys and Tomas Milašauskas. This follows the announcement on 21 August 2025, where Northern Horizon Capital AS announced the signing of a share purchase agreement with the partners of the private investment company Grinvest. In accordance with the share purchase agreement, the transaction will be completed within 10 days of the approval. For additional information, please contact: Christoffer Abramson Group CEO of Northern Horizon A/S E-mail: christoffer.abramson@nh-cap.com www.baltichorizon.com Contact...

Continue reading

Marquette National Corporation Reports Third Quarter 2025 Results

CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Marquette National Corporation (OTCQX: MNAT) today reported year-to-date net income of $10.3 million compared to net income of $14.2 million for the first nine months of 2024. Earnings per share for the first nine months of 2025 were $2.37, as compared to income of $3.25 per share for the comparable period in 2024. At September 30, 2025, total assets were $2.25 billion, an increase of $41 million, or 2%, compared to $2.21 billion at December 31, 2024. Total loans increased by $34 million to $1.44 billion compared to $1.41 billion at the end of 2024. Total deposits increased by $36 million, or 2%, to $1.78 billion compared to $1.74 billion at the end of 2024. Paul M. McCarthy, Chairman & CEO, said, “the primary reason for the decrease in consolidated earnings was a lower level of unrealized...

Continue reading

SUTNTIB AB Tewox publishes its factsheet for the third quarter of 2025

Vilnius, Lithuania, Oct. 29, 2025 (GLOBE NEWSWIRE) — SUTNTIB AB Tewox (the Company) publishes its factsheet, providing information about Company’s financial indicators and key events as at 30 September 2025. 2025 Q3 KEY EVENTSConstruction of three new grocery stores in Vilnius, Klaipėda and Klaipėda district has started:Vilnius: a grocery store with a GLA of ~1,788 sqm will be leased to the supermarket chain Iki. The total investment is projected at around 5 mEUR, with opening planned in 2026. Klaipėda: a grocery store with a GLA of ~2,127 sqm will be leased to the supermarket chain Lidl. The total investment is projected at around 6 mEUR, with opening planned in 2026. Klaipėda district: a grocery store with a GLA of ~2,000 sqm will be leased to the supermarket chain Iki. The total investment is projected at around 5 mEUR,...

Continue reading

Sampo Group’s results for January–September 2025 will be published on 5 November 2025

Sampo plc, press release, 29 October 2025 at 11:00 am EET Sampo Group’s results for January–September 2025 will be published on 5 November 2025 Sampo Group will publish the Interim Statement for January–September 2025 on 5 November 2025 around 8:30 am Finnish time (6:30 am UK time). The report, the investor presentation, and a video review with Group CEO Morten Thorsrud will be available at www.sampo.com/result. Conference call 5 November at 10:30 am Finnish time (8:30 am UK time) To ask questions, please join the teleconference by registering using the following link: https://palvelu.flik.fi/teleconference/?id=50051477. Upon registration, you will receive phone numbers as well as a conference ID and user ID to access the conference. If you wish to ask a question, please dial #5 on your telephone keypad to enter the queue. Group...

Continue reading

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

Philips iFR technologyOctober 29, 20253-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-up Additional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteriesAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking results from the iMODERN trial (Instantaneous wave-free Ratio Guided Multivessel Revascularisation During PCI for Acute Myocardial Infarction) at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference,...

Continue reading

NXP Improves Battery Health Monitoring with EIS Capable Battery Management Chipset

NXP Improves Battery Health Monitoring with EIS Capable Battery Management ChipsetNXP brings lab-grade diagnostics into vehicles, enhancing battery health insights and expanding NXP’s electrification portfolio with advanced monitoring capabilities.NXP unveils industry-first, battery management system (BMS) chipset with built-in Electrochemical Impedance Spectroscopy (EIS) using precise hardware-based synchronization of all battery cell measurements within a single high-voltage battery pack Brings lab-grade diagnostics into vehicles, enhancing battery health insights and expanding NXP’s electrification portfolio with advanced monitoring capabilities Simplified and cost-efficient battery cell monitoring allows automakers track battery health, improve electric vehicle (EV) safety, and support fast chargingEINDHOVEN, The Netherlands,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.